Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition

American Journal of Cancer Research

Volumn 5, Issue 4, 2015, Pages 1308-1318

  Liu, Can ^a,b   Zeng, Yan ^b   Dai, Long Hai ^b   Cai, Tian Yu ^a   Zhu, Yue Ming ^b   Dou, De Quan ^a   Ma, Lan Qing ^a   Sun, Yuan Xia ^b  

^a BEIJING UNIVERSITY OF AGRICULTURE   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Apoptosis; ERK1 2; Mogrol; Mogrosides; STAT3

Indexed keywords

ANTILEUKEMIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MOGROL; PROTEIN BCL 2; PROTEIN P21; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 85006190151     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Huang T, Lin J, Cao J, Zhang P, Bai Y, Chen G, Chen K. An exopolysaccharide from Tricho-derma pseudokoningii and its apoptotic activity on human leukemia K562 cells. Carbohydr Polym 2012; 89: 701-708.
2. Singh A, Dilnawaz F, Sahoo SK. Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One 2011; 6: e26803.
3. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-954.
4. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Bba-mol Cell Res 2007; 1773: 1213-1226.
5. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A. Constitutive activation of STAT3 in human prostate tumors and cell lines direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659-6666.
6. Monami G, Gonzalez EM, Hellman M, Gomella LG, Baffa R, Iozzo RV, Morrione A. Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res 2006; 66: 7103-7110.
7. Chan KS, Sano S, Kiguchi K, Anders J, Ko-mazawa N, Takeda J, DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004; 114: 720-728.
8. Kang CD, Yoo SD, Hwang BW, Kim KW, Kim DW, Kim CM, Kim SH, Chung BS. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leukemia Res 2000; 24: 527-534.
9. Woessmann W, Mivechi NF. Role of ERK activation in growth and erythroid differentiation of K562 cells. Exp Cell Res 2001; 264: 193-200.
10. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003; 101: 1535-1542.
11. Zisen H, Jianwei W, Shudan S, Yaping W. Ef-fects of angelica polysaccharide on expression and activation of JAK2 and STAT3 in K562 leukemia cells. Chinese Journal of Anatomy. 2009; 1: 008.
12. Qin X, Xiaojian S, Ronggan L, Yuxian W, Zhunian T, Shouji G, Heimbach J. Subchronic 90-day oral (Gavage) toxicity study of a Luo Han Guo mogroside extract in dogs. Food Chem Toxicol 2006; 44: 2106-2109.
13. Di R, Huang MT, Ho CT. Anti-inflammatory activities of mogrosides from Momordica grosvenori in murine macrophages and a murine ear edema model. J Agr Food Chem 2011; 59: 7474-7481.
14. Suzuki YA, Tomoda M, Murata Y, Inui H, Sugiura M, Nakano Y. Antidiabetic effect of long-term supplementation with Siraitia grosvenori on the spontaneously diabetic Goto-Kakizaki rat. Brit J Nutr 2007; 97: 770-775.
15. Xiangyang Q, Weijun C, Liegang L, Ping Y, Bijun X. Effect of a Siraitia grosvenori extract containing mogrosides on the cellular immune system of type 1 diabetes mellitus mice. Mol Nutr Food Res 2006; 50: 732-738.
16. Takasaki M, Konoshima T, Murata Y, Sugiura M, Nishino H, Tokuda H, Matsumoto K, Kasai R, Yamasaki K. Anticarcinogenic activity of natural sweeteners, cucurbitane glycosides, from Momordica grosvenori. Cancer Lett 2003; 198: 37-42.
17. Liu C, Liu J, Rong Y, Rong L. Preparation of productive and highly purified mogrosides from Siraitia grosvenorii. Afr J Biotechnol 2013; 10: 7021-7025.
18. Chen T. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 1977; 104: 255-262.
19. Shacter E, Williams JA, Lim M, Levine RL. Dif-ferential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radical Biol Med 1994; 17: 429-437.
20. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
21. Vaux D, Cory S, Adams J. Bcl-2 and cell survival. Nature 1988; 335: 440-442.
22. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
23. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20: 2499-2513.
24. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13: 65-70.
25. Cagnol S, Chambard JC. ERK and cell death: Mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 2010; 277: 2-21.
26. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
27. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937-947.
28. Cossa G, Lanzi C, Cassinelli G, Carenini N, Arri-ghetti N, Gatti L, Corna E, Zunino F, Zaffaroni N, Perego P. Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and-resistant ovarian carcinoma ce-lls. Cancer Lett 2014; 347: 212-224.
29. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002; 8: S27-S31.
30. Gerhardt D, Bertola G, Dietrich F, Figueiró F, Zanotto-Filho A, Moreira Fonseca JC, Morrone FB, Barrios CH, Battastini AMO, Salbego CG. Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β. Urol Oncol-Semin Ori 2014: 36: e31-36, e39.
31. Subramanian M, Shaha C. Up-regulation of Bcl-2 through ERK phosphorylation is associated with human macrophage survival in an estrogen microenvironment. J Immunol 2007; 179: 2330-2338.
32. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood 2000; 95: 1014-1022.
33. Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, War-rell RP, Pandolfi PP. Arsenic Trioxide and Me-larsoprol Induce Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-RAR Independent Manner. Blood 1998; 92: 1497-1504.
34. Fukada T, Ohtani T, Yoshida Y, Shirogane T, Nishida K, Nakajima K, Hibi M, Hirano T. STAT3 orchestrates contradictory signals in cytoki-ne induced G1 to S cell-cycle transition. EMBO J 1998; 17: 6670-6677.
35. Nakatake M, Kakiuchi Y, Sasaki N, Murakami-Murofushi K, Yamada O. STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle 2007; 6: 1495-1500.
36. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
37. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
38. Mencalha AL, Binato R, Ferreira GM, Du Ro-cher B, Abdelhay E. Forkhead box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line. PLoS One 2012; 7: e48160.
39. Seidel HM, Lamb P, Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 2000; 19: 2645-2656.
40. Darnell JE. STATs and gene regulation. Science 1997; 277: 1630-1635.
41. Krasilnikov M, Ivanov VN, Dong J, Ronai ZE. ERK and PI3K negatively regulate STAT-trans-criptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003; 22: 4092-4101.
42. Haspel R, Salditt-Georgieff M, Darnell J Jr. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 1996; 15: 6262.
43. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-5190.
44. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Co-nnell-Crowley L, Swindell E. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6: 387-400.
45. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science 1996; 272: 719-722.
46. Ogryzko VV, Wong P, Howard BH. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997; 17: 4877-4882.
47. Radhakrishnan SK, Feliciano CS, Najmabadi F, Haegebarth A, Kandel ES, Tyner AL, Gartel AL. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 2004; 23: 4173-4176.